Cardinal Health agrees to pay $44 million to the Department of Justice
Payment resolves the outstanding civil penalty portion of the company's 2012 administrative settlement with this US DEA.
Cardinal Health has reached a nationwide settlement with the Federal government, resolving the outstanding civil penalty portion of the company's 2012 administrative settlement with the US Drug Enforcement Agency (DEA). The 2012 settlement resulted in a 2-year suspension of Cardinal Health's registration to distribute controlled substances from its Lakeland, Fla. distribution centre, but did not at the time resolve the Government's civil penalty claims.
Under this settlement, Cardinal Health has agreed to pay $44 million to the Department of Justice (DOJ) to resolve this matter. The DOJ, including the DEA and the United States Attorneys' Offices for the MD Florida, the Southern District of New York, the District of Maryland, and the WD Washington and all other districts across the country have agreed to take no further administrative or civil action on these and related matters. Cardinal Health had previously disclosed the civil fines claims and a related accrual of $44 million in its public securities filings.
"These agreements allow us to move forward and continue to focus on working with all participants in addressing the epidemic of prescription drug abuse," said Craig Morford, Chief Legal and Compliance Officer, Cardinal Health. "To combat the scourge of opioid abuse successfully, this must be a collaborative effort that includes all parties - the regulators, who set and license supply; the manufacturers, who produce medications; the physicians, who treat patients and prescribe medications; and the pharmacists, who fill those prescriptions. Collectively, we must focus on combatting the ever-changing tactics employed by those determined to divert medications for illegitimate use. Cardinal Health is committed to working with both public and private partners to do our part and find solutions."
Related News
-
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance